文章名稱引用次數

• Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade54
• Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation13
• Demonstrating the value of the oncology pharmacist within the healthcare team12
• Pembrolizumab-induced myasthenia gravis: A fatal case report11
• Adherence to oral chemotherapy: Challenges and opportunities11
• Updates and novel treatments in urothelial carcinoma9
• Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen8
• Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events8
• Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors7
• Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma7